This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): Omnaris HFA MDI, Ciclesonide hydrofluoroalkane (HFA) metered-dose inhaler (MDI), CIC-HFA
Description: OMNAIR is a corticosteroid. Corticosteroids act at a number of levels on the immune system to reduce inflammation.
As well as being available as a nasal metered dose inhaler (MDI) using an HFA propellant, Omnaris is available as an intranasal spray (Omnaris). The goal of the MDI is to avoid run-off of medication down the back of the throat and forward nasal drip.
Deal Structure: In January 2008, Nycomed granted Sepracor the exclusive development, marketing and commercialisation rights for Ciclesonide in the United States. Nycomed will receive an upfront payment of $150 million and subsequent payments upon accomplishment of various development and sales milestones, which could include up to an additional $280 million over the life of the agreement if all milestones are met. Nycomed will also receive compensation for providing finished product and royalties on sales of Ciclesonide products.
Nycomed retains all rights to Ciclesonide outside the United States and also has rights for the territories outside the United States to certain line extensions and additional products developed by Sepracor under the agreement.
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share....See full deal structure in Biomedtracker
Partners: AstraZeneca PLC
Additional information available to subscribers only: